Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab extension study in chronic spontaneous urticaria
NCT02649218Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Event at Week 64. Started May 2016; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02649218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649218.